MedTrace Logo

A Pharmacist Intervention for Monitoring and Treating Hypertension Using Bidirectional Texting

NCT03986931 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 535

Last updated 2025-01-22

Study results available
· View outcomes & findings →

Summary

Bidirectional texting is an effective way to collect home blood pressure (BP) measurements from subjects, but collecting BP measurements and sending them to physicians does not necessarily lead to decreased BP. Pharmacist interventions have been successful in decreasing subject BP. However, pharmacists are expensive, and in successful interventions, spent a substantial amount of time collecting home BP measurements. In this study, a proven pharmacist intervention will be added to a bidirectional texting program to determine if a combined pharmacist-bidirectional texting intervention is successful at decreasing subject BP and increasing subject BP treatment intensification in a cost-effective manner. This study will be a cluster-randomized, controlled trial of a new intervention.

Conditions

Interventions

OTHER

Experimental: Pharmacist-Bidirectional Texting Group

The goal of this intervention is to determine if bidirectional texting and pharmacist monitoring will improve blood pressure control.

OTHER

Active Comparator: Control Group

This group will receive bidirectional texting, but no pharmacist monitoring.

Sponsors & Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)

    collaborator NIH

  • Linnea Polgreen

    lead OTHER

Principal Investigators

  • Linnea A Polgreen, PhD · University of Iowa

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-25
Primary Completion
2023-06-22
Completion
2023-06-22

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03986931 on ClinicalTrials.gov